tbuckley/cabot-search huggingface dataset:
Adoptive T CELL Immunotherapy Restores Targeted Antiviral Immunity in Primary Immunodeficiency Disorders
Authors: Michael Keller, Patrick J. Hanley, Sam Darko, Jamie Hoover, Lauren Roesch, Sarah McCormack, Haili Lang, Elizabeth Williams, Cecilia Barese, Allistair Abraham, David Jacobsohn, Evelio Perez-Albuerne, Kirsten Williams, Blachy Davila, Roberta Adams, Amy Keating, Jennifer Kanakry, Dimana Dimitrova, Nancy Bunin, Jennifer Heimall, Daniel Douek, Catherine M. Bollard
Journal: Journal of Allergy and Clinical Immunology (2017)
The familiality of primary brain tumors as studied in the Utah Population Database (UPDB)
Authors: D. S. Keith, D. T. Blumenthal, L. A. Cannon-Albright
Journal: Journal of Clinical Oncology (2004)

1526 Background: The UPDB is a unique database linking 2.5 million Utah individuals with genealogical data to 80,000 Utah SEER cancer registry records since 1973. The familial nature of cancer has been well studied using this resource. Here we use similar techniques to investigate 1550 individuals diagnosed with brain tumors. Methods: We estimated the relative risk of brain cancer in relatives of brain cancer cases using internal age- and sex-specific rates of brain cancer estimated from UPDB. We estimated the average relatedness of brain cancer cases (compared to the average relatedness for 1000 matched control groups) using the Genealogical Index of Familiality measure, which extends beyond first degree relatives and looks at all pair wise relationships between cases. We considered all 1550 brain cancers as a group, the subgroup of 364 astrocytomas and the subgroup of 571 glioblastomas. Results: The relative risk for brain cancer in 1st degree relatives of all brain cancer cases is 2.78 (p=5.1xe-7). The average relatedness of all brain cancers was significantly higher than expected in controls (p=0.03). The relative risk for brain cancer in 1st degree relatives of cases with astrocytoma was 3.03. The astrocytoma subgroup also showed significantly higher average relatedness than controls (p=0.002). The relative risk of all brain cancers in the first-degree relatives of glioblastoma cases was 2.60 (p=2.0xe-3). The glioblastoma subgroup of cases did not show significantly higher average relatedness than expected in controls (p=0.68). Conclusions: The UPDB resource provides strong evidence for a familial component in brain cancer that seems to extend beyond first-degree relatives. The subgroup of astrocytoma showed more evidence for underlying genetic component than the glioblastoma subgroup. Study of high-risk pedigrees could allow increased understanding of brain cancer predisposition genes. No significant financial relationships to disclose.
How to integrate vital interdisciplinary information in a non-closed-loop system?
Authors: Jack Toshimine Seki, Dominic Tsang, Diana Incekol, Ian Brandle, Emma Paisley, Roy Lee, Rita Kwong, Marina Kaufman, Monika Karolina Krzyzanowska, Vishal Kukreti
Journal: Journal of Clinical Oncology (2012)

314 Background: History of hypersensitivity reactions (HSR) must be readily accessible to ensure patient safety while receiving chemotherapy. While documentation of HSR is a routine process, gaps are found in maintaining vital information amongst various stand-alone systems (SAS). Centralized documentation (CD) by frontline nursing staff in the Electronic Patient Record is key to reduce risk. Pharmacists refer to CD for HSR information when processing chemotherapy. We developed and evaluated a technology-based workaround approach as a possible solution to a non-closed-loop system. Methods: An e-clinical point of care documentation tool was designed and built for nursing data collection of HSR details within the Electronic Patient Record. Vital parameters necessary for “complete” HSR documentation were outlined in a cue card, including time of reaction, reaction drug, volume and rate of infusion, management, vital signs and objective symptoms, re-challenge or discontinuation, and patient outcome. This cue card standardizes e-documentation. Pre- and post-system rollout survey was used to gauge effectiveness of CD by nursing and pharmacists. Results: Over a 6-month period, there were 173 HSRs in 11,754 patient visits (1.5%), with variability in collection of vital documentation in relation to roll out of the e-tool. In the pre-CD rollout phase (May 25 to September 12, 2011) 108 HSRs were identified that were documented in multiple locations including an electronic prescribing SAS (86%) and the chemotherapy nursing paper record (77%). In the post-CD phase (April 23 to June 23, 2012) 65 HSRs were identified, 46% of which were documented in CD, 72% in the electronic prescribing SAS, and 85% in paper record. Six of 7 pharmacists (85%) and 7 of 10 nurses (70%) who were surveyed indicated that the new CD documentation process was “effective” or “significantly effective”. Conclusions: As non-fully integrated systems exist in current environments, technology workarounds should be used to “close the loop”. E-Clinical documentation is an upcoming centralized technology solution, which we have used with promising initial adoption results. Formal e-documentation tools can lead to more detailed documentation than current processes.
Galectin-9 Ameriorates Acute GVHD by Inducing T-Cell Apoptosis and Increasing Regulatory T Cell.
Authors: Kazuki Sakai, Eri Kawata, Eishi Ashihara, Akira Yamauchi, Shinya Kimura, Hideyo Hirai, Mitsuomi Hirashima, Norio Yoshimura, Taira Maekawa
Journal: Blood (2009)
T-Cell Function in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Following Alemtuzumab (Campath®) or Fludarabine Treatment.
Authors: Shahryar Kiaii, Fariba Mozaffari, Jeanette Lundin, Reza Rezvany, Aniruddha Chudhury, Håkan Mellstedt, Anders Osterborg
Journal: Blood (2004)
Guideline-concordant surveillance and follow-up care among low-income patients with breast cancer: The role of primary care medical homes.
Authors: Stephanie B. Wheeler, Racquel Elizabeth Kohler, Ravi K. Goyal, Kristen Hassmiller Lich, Alexis Moore, Timothy Smith, Cathy Melvin, Katherine Elizabeth Reeder-Hayes, Marisa E. Domino
Journal: Journal of Clinical Oncology (2012)

171 Background: Community Care of North Carolina (CCNC) initiated an innovative medical home (MH) program in the 1990s to improve primary care in Medicaid-insured populations. CCNC has been successful in improving asthma, diabetes, and cardiovascular outcomes, but has not been evaluated in the context of cancer care. We sought to determine whether MH enrollment was associated with guideline-concordant surveillance and follow-up care among breast cancer survivors. Methods: Using state cancer registry records matched to Medicaid claims, we identified women ages 18-64 diagnosed with stage 0, I, or II breast cancer from 2003-2007 and tracked their CCNC enrollment. Using published American Society for Clinical Oncology breast cancer survivorship guidelines to define our outcomes, we employed multivariate logistic regressions to examine correlates of receipt of surveillance mammogram and at least two physical exams within 15 months post-diagnosis. Results: In total, 840 women were included in our sample. Approximately half were enrolled in a CCNC MH during the study period, 38% were enrolled for more than 7 months post-diagnosis. Enrollment in a MH for at least 7 months post-diagnosis was strongly associated with receiving guideline-recommended surveillance mammogram (p&lt;0.01) and at least 2 physical exams (p&lt;0.01) within 15 months post-diagnosis. Conclusions: Results suggest that MH enrollment is associated with higher quality breast cancer survivorship care among women insured by Medicaid. Given the growing population of cancer survivors and increased emphasis on primary care MH, more research is needed to explore how medical homes can enhance and ensure the provision of guideline-recommended care during cancer survivorship.
A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America
Authors: Daniel Suez, Gregely Krivan, Stephen R. Jolles, Iftikhar Hussain, Mark R. Stein, Sudhir Gupta, Kenneth Paris, Martin van Hagen, Nicholas Brodszki, Barbara McCoy, Leman Yel
Journal: Journal of Allergy and Clinical Immunology (2017)
Abstract 20173: Cardiac Microrna-208a is Upregulated and Positively Correlates With Cardiomyocyte Apoptosis in End Stage Dilated Cardiomyopathy
Authors: Hasahya Tony, Kunwu Yu, Ma Wenhan, Xiaoqi Zhao, Yuzhou Liu, Qiutang Zeng
Journal: Circulation (2015)

Introduction: Cardiac miR-208a is dysregulated in several cardiac diseases in which it is associated with adverse outcomes. Our group has previously demonstrated that miR-208a promotes cardiomyocyte apoptosis. Given that many cardiac diseases end with dilated cardiomyopathy, we investigated if miR-208a is upregulated in end stage dilated cardiomyopathy (DCM), and if its expression correlates with cardiomyocyte apoptosis. Methods and Results: Left ventricular samples were collected from nine patients with end stage DCM who underwent cardiac transplant, and 8 normal controls. miR-208a levels were analyzed by real time-PCR, and apoptosis assay done by TUNEL method. miR-208a was 5.8 times higher in left ventricular samples of end stage DCM patients compared to controls, p=0.014. Patients with DCM also had a significantly higher percentage apoptosis compared to controls, p=0.009,(Figure 1A shows representative TUNEL stained images with increased cardiomyocyte apoptosis in DCM). The level of miR-208a showed a significant positive correlation with percentage cardiomyocyte apoptosis rho(0.597), p=0.011. Conclusion: Taken together, we showed that miR-208a is elevated in end stage DCM and its levels are positively correlated with cardiomyocyte apoptosis. Targeted silencing of miR-208a may thus be beneficial in DCM and other cardiac diseases that end up in DCM.
Short and Long Term Efficacy of Autologous Bone Marrow Cells To Support Intensive Chemotherapy in Patients Failing Peripheral Blood Stem Cell Mobilization.
Authors: Tara Seshadri, Khalil Al-Farsi, Julie Stakiw, Clement Ma, Ronnie Saragosa, Armand Keating, Michael Crump, John Kuruvilla
Journal: Blood (2007)
Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).
Authors: Martin J. Van Den Bent, Khê Hoang-Xuan, Alba Ariela Brandes, Johan M Kros, Mathilde C.M. Kouwenhoven, Martin J. B. Taphoorn, Jean-Yves Delattre, Hans J.J.B. Bernsen, Marc Frenay, Cees Tijssen, Wolfgang Grisold, Laszlo Sipos, Roelien H. Enting, Winand N.M. Dinjens, Pim French, Charles J Vecht, Anouk Allgeier, Denis A. Lacombe, Thierry Gorlia
Journal: Journal of Clinical Oncology (2012)

2 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
Attenuated Essential Thrombocytemia Induced in Mice by the Expression of AML1/MDS1/EVI1 (AME) or an AME Mutant: Comparison between Two New Models of Myeloproliferative Disorders.
Authors: Ciro R. Rinaldi, Vitaly Senyuk, Leopoldo Laricchia-Robbio, Jerome Dickstein, Giuseppina Nucifora
Journal: Blood (2006)
Wearable Recording Devices for Surgical Training—Reply
Authors: H. Randall Beard, Alejandro J. Marquez-Lara, Kamran S. Hamid
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Trends in screening for colorectal cancer in France
Authors: J. Viguier, A. Calazel Benque, M. Mahjoubi, X. Pivot, J. Morère, J. Blay, Y. Coscas, C. Roussel, F. Eisinger
Journal: Journal of Clinical Oncology (2009)

1538 Background: In France, after a pilot population-based screening program in 23 districts (2002–2003), a national organized program was progressively implemented starting in 2005. The EDIFICE 2 survey was conducted in 2008, 3 years after EDIFICE 1, to provide a better understanding of French people's participation in colorectal screening programs and to assess the evolution between the two periods. Methods: This second nationwide observational study, EDIFICE 2, was conducted in January 2008 among a representative sample of 1,801 subjects aged between 40 and 85 years old. The analysis focused on the target population of the national screening program (50–74 years old). Results: In 2008, 38% of subjects between 50 and 74 years (N = 928) had undergone a screening test for colorectal cancer (including fecal test or colonoscopy) versus 25% in 2005 (p &lt; 0.05); 32% of the unscreened population (N = 575) planned to undergo a test. Colorectal cancer screening increased significantly in all age groups, especially between 65 and 69 years, and for both sexes. A most significant increase can be observed in districts with pilot programme (+ 21%). Factors influencing the probability of screening were: being encouraged by the family circle, living in a couple, the existence of a case of cancer (especially colorectal cancer) in the family circle, and fear of colorectal cancer. The main reasons for not performing the screening were: not feeling concerned, no recommendation by the GP, carelessness, no symptoms, and fear of exams or results. Conclusions: The objective rate of participation (50%), can be reached by motivating the unscreened population already planning to perform a test. The results in the pilot districts show the effectiveness of an organization of the screening. This trend of increasing testing will probably be confirmed in the future if the reasons for non-attendance in an organized program are addressed. No significant financial relationships to disclose.
Ataxia Telangiectasia Presenting with Hypogammaglobulinemia and High IgM Levels, Cutaneous Granulomas, and Expansion of CD21(lo) T-bet(+) B Cells
Authors: Heather B. Minto, Kira Rubtsova, Paul R. Reynolds, Erwin W. Gelfand
Journal: Journal of Allergy and Clinical Immunology (2017)
Rad51 Degradation: Role in Oncolytic Virus—Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma
Authors: Jianfang Ning, Hiroaki Wakimoto, Cole Peters, Robert L. Martuza, Samuel D. Rabkin
Journal: JNCI Journal of the National Cancer Institute (2017)

Background: Clinical success of poly(ADP-ribose) polymerase inhibitors (PARPi) has been limited to repair-deficient cancers and by resistance. Oncolytic herpes simplex viruses (oHSVs) selectively kill cancer cells, irrespective of mutation, and manipulate DNA damage responses (DDR). Here, we explore potential synthetic lethal-like interactions between oHSV and PARPi. Methods: The efficacy of combining PARPi, oHSV MG18L, and G47Δ in killing patient-derived glioblastoma stem cells (GSCs) was assessed using cell viability assays and Chou-Talalay synergy analysis. Effects on DDR pathways, apoptosis, and cell cycle after manipulation with pharmacological inhibitors and lentivirus-mediated knockdown or overexpression were examined by immunoblotting and FACS. In vivo efficacy was evaluated in two GSC-derived orthotopic xenograft models (n = 7–8 per group). All statistical tests were two-sided. Results: GSCs are differentially sensitive to PARPi despite uniform inhibition of PARP activity. oHSV sensitized GSCs to PARPi, irrespective of their PARPi sensitivity through selective proteasomal degradation of key DDR proteins; Rad51, mediating the combination effects; and Chk1. Rad51 degradation required HSV DNA replication. This synthetic lethal-like interaction increased DNA damage, apoptosis, and cell death in vitro and in vivo. Combined treatment of mice bearing PARPi-sensitive or -resistant GSC-derived brain tumors greatly extended median survival compared to either agent alone (vs olaparib: P≤.001; vs MG18L: P = .005; median survival for sensitive of 83 [95% CI = 77 to 86], 94 [95% CI = 75 to 107], 102 [95% CI = 85 to 110], and 131 [95% CI = 108 to 170] days and for resistant of 54 [95% CI = 52 to 58], 56 [95% CI = 52 to 61], 62 [95% CI = 56 to 72], and 75 [95% CI = 64 to 90] days for mock, PARPi, oHSV, and combination, respectively). Conclusions: The unique oHSV property to target multiple components of DDR generates cancer selective sensitivity to PARPi. This combination of oHSV with PARPi is a new anticancer strategy that overcomes the clinical barriers of PARPi resistance and DNA repair proficiency and is applicable not only to glioblastoma, an invariably lethal tumor, but also to other tumor types.
Results of First-in-Man Phage Idiotype Vaccine Study in Patients with Multiple Myeloma.
Authors: Tim Roehnisch, Wolfgang Nagel, Thomas Boehm, Mariel Donceau, Carole Bourquin, Dilda A. Roehnisch, Beata Rutz, Christian Straka, Bertold Emmerich, Fuat S. Oduncu
Journal: Blood (2009)
The efficacy and safety of re-administration of rasburicase for patients with hematological malignancies
Authors: Kyoko Imamura, Keiji Sugiyama, Yuta Hasegawa, Hiroyuki Nakamura, Yasuhiro Suzuki, Takashi Tokunaga, Yasuhiko Miyata, Akane Kunitomi, Hiroatsu Iida, Hirokazu Nagai
Journal: Annals of Oncology (2016)
Towards the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma: do not lose the forest looking at the tree
Authors: E. De Carlo, L. Gurrieri, G. De Maglio, L. Gerratana, V. Buoro, S. Rizzato, A. Follador, M. Giavarra, M. Isola, M. Skrap, G. Fasola, F. Puglisi, S. Pizzolitto
Journal: Annals of Oncology (2016)
IgG-Secreting B-Cell Lymphoplasmocytoid Leukaemia : Molecular Characterization of Igh Rearrangements.
Authors: Laurence Lode, Surinder S. Sahota, Soraya Wuilleme, Steven Richebourg, Marion Eveillard, Regis Bataille, Herve Avet Loiseau, Richard Garand
Journal: Blood (2008)
Erratum: Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer
Authors: Xifeng Wu, Yuanqing Ye, Lambertus A Kiemeney, Patrick Sulem, Thorunn Rafnar, Giuseppe Matullo, Daniela Seminara, Teruhiko Yoshida, Norihisa Saeki, Angeline S Andrew, Colin P Dinney, Bogdan Czerniak, Zuo-feng Zhang, Anne E Kiltie, D Timothy Bishop, Paolo Vineis, Stefano Porru, Frank Buntinx, Eliane Kellen, Maurice P Zeegers, Rajiv Kumar, Peter Rudnai, Eugene Gurzau, Kvetoslava Koppova, Jose Ignacio Mayordomo, Manuel Sanchez, Berta Saez, Annika Lindblom, Petra de Verdier, Gunnar Steineck, Gordon B Mills, Alan Schned, Shen-Chih Chang, Jie Lin, David W Chang, Katherine S Hale, Tadeusz Majewski, H Barton Grossman, Steinunn Thorlacius, Unnur Thorsteinsdottir, Katja K H Aben, J Alfred Witjes, Kari Stefansson, Christopher I Amos, Margaret R Karagas, Jian Gu
Journal: Nature Genetics (2009)
Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome
Authors: Evangelos Terpos, Bouchra Asli, Dimitrios Christoulas, Jean-Claude Brouet, Efstathios Kastritis, Michel Rybojad, Meletios Athanasios Dimopoulos, Jean Paul Fermand
Journal: Blood (2011)
Follow-up schedule based on evidence of melanoma recurrences in 200 patients, a monoinstitutional experience
Authors: D. Mangiola, S. Brugnara, A. Ferro, M. Sicher, M. Bertolin, R. Triolo, A. Veccia, M. Dipasquale, O. Caffo, E. Galligioni
Journal: Annals of Oncology (2016)
Continuous High-Dose Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia –Single-Center Experience.
Authors: Sandra Basic-Kinda, Igor Aurer, Dino Dujmovic, Ivo Radman, Dubravka Sertic, Klara Dubravcic, Koraljka Gjadrov-Kuvezdic, Drago Batinic, Mirna Sucic, Boris Labar
Journal: Blood (2009)
The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).
Authors: Jacob M. Rowe, Xiaopan Yao, Peter A. Cassileth, Frederick R. Appelbaum, Peter H. Wiernik, Charles Schiffer, Mark R. Litzow, Selina Luger, John M. Bennett, Hillard M Lazarus, Martin S Tallman
Journal: Blood (2008)
Proof of concept of correlation between progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with advanced renal-cell carcinoma (mRCC): Final results of a randomized phase II study comparing sorafenib plus interleukin-2 (IL-2) versus sorafenib alone: The ROSORC trial.
Authors: Elena Verzoni, Sergio Bracarda, Sergio Ricci, Cosimo Sacco, Laura Ridolfi, Camillo Porta, Rosalba Miceli, Nicoletta Zilembo, Emilio Bajetta, Giuseppe Procopio
Journal: Journal of Clinical Oncology (2013)

e15589 Background: The outcome analyses of the randomized phase 2 ROSORC trial, did not show any difference in terms of PFS between mRCC patients undergoing first-line treatment with sorafenib plus IL-2 versus sorafenib monotherapy (7.3 versus 6.9 months in favour of the combination arm; p= 0.109). (Procopio et al BJC 2011). Overall survival analyses are here reported. Methods: In this open-label phase 2 prospective study, 128 treatment-naïve patients with mRCC were randomized to receive either sorafenib 400 mg twice daily plus subcutaneous IL-2 4.5 MIU five times a week for 6 weeks every eight weeks (Arm A), or sorafenib alone (Arm B). The primary endpoint was PFS, while the secondary endpoint was OS. Survival analyses were evaluated by Kaplan-Meier plots and compared by two-sided log-rank test. Results: After a median follow up of 58 months (interquartile range 28-63), the median OS was 38 and 33 months in arm A and B respectively (p= 0.667). The 5-year OS was 26.3 % (95% CI: 15.9-43.5) and 23.1% (95 % CI: 13.2-40.5) in the combination and single agent arm, respectively. Overall we observed 85 deaths and among them, 42 occurred in the Arm B. Overall, 49 (74 %) and 48 (77 %) patients in the Arm A and B, respectively, received at least one targeted therapy (TT) after disease progression, including sunitinib, everolimus, axitinib or temsirolimus. Most common adverse events (AEs) included fatigue, hand-foot syndrome, hypertension and diarrhea and were mild in grade (Grade 1-2). Grade 3-4 AEs were documented in 38 % and 25 % of patients receiving combination and single agent treatment, respectively. Conclusions: While the PFS observed was in keeping with previous literature data regarding sorafenib, either as a single agent or in combination, the OS dramatically improved results reported so far in prospective randomized trials. This outcome suggests lack of correlation between PFS and OS and a synergistic effect of sequential TTs following sorafenib failure. Clinical trial information: NCT00609401.
Total Body Irradiation (TBI), Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Advanced Pediatric Hematologic Malignancies.
Authors: Demetrios Petropoulos, Laura L. Worth, Craig A. Mullen, Anita Mahajan, Mary S. Choroszy, Ka Wah Chan
Journal: Blood (2004)
BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia
Authors: Srividya Swaminathan, Chuanxin Huang, Bjorn Titz, Maike Buchner, Huimin Geng, Thomas G Graeber, Cheryl L Willman, Kazuhiko Igarashi, Ari Melnick, Markus Muschen
Journal: Blood (2011)